The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | FLT3 inhibitors: revolutionizing the management of AML
Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of FLT3 inhibitors in the treatment of acute myeloid leukemia (AML). He highlights several clinical trials that have pioneered the approval of various FLT3 inhibitors in both the frontline and relapsed/refractory (R/R) setting. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
